Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by
blocking the enzymes necessary for their growth. This phase II trial is studying how well
sorafenib works in treating patients with persistent or recurrent ovarian epithelial or
peritoneal cancer.